Applicant(s)/Patent Under Application/Control No. Reexamination WARRELL ET AL. 09/709,170 Art Unit Page 1 of 2 **Notice of References Cited** Examiner 1635 Terra C. Gibbs U.S. PATENT DOCUMENTS Classification Name Date Document Number MM-YYYY Country Code-Number-Kind Code US-Α US-В US-С US-D US-Ε US-F US-G US-Н US-١ US-J US-K US-L FOREIGN PATENT DOCUMENTS Classification US-M Name Date Country Document Number MM-YYYY Country Code-Number-Kind Code Ν 0 Ρ Q R s NON-PATENT DOCUMENTS Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) Т Webb et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. The Lancet, 1997 vol. 349:1137-1141. Jansen, B. A Phase I-II Study with Dacarbazine and bcl-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in υ patients with advanced malignant melanoma. American Society of Clinical Oncology, 1999 Abstract. Klasa et al. Eradication of Human Non-Hodkin's Lymphoma in SCID mice by Bcl-2 antisense Oligonucleotides combined with lose-dose cyclophosphamide. Clinical Cancer Research, 2000 Vol. 6:2492-2500. Tortora et al. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with

W

cytotoxic drugs or biologic agents. Antisense and Nucleic acid Drug Development, 1998 Vol. 8:141-145. *A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Applicant(s)/Patent Under Application/Control No. Reexamination WARRELL ET AL. 09/709,170 Art Unit **Notice of References Cited** Page 2 of 2 Examiner 1635 Terra C. Gibbs

				U.S. PATENT DOCUMENTS	Classification
	1	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	
1	A	US-	 		
7	В	US-			
1	С	US-			
	D	US-	ļ		
	E	US-	<u> </u>		
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	K	US-			
_	1	US-			
_	М	US-		FOREIGN PATENT DOCUMENTS	Classification

	M	US-		OREIGN PATENT DOC	UMENTS	Classification
		Document Number	Date	Country	Name	Classification
*		Country Code-Number-Kind Code	MM-YYYY			
	N					
	0					
	Р					
	Q					
	R		 			
	s					
				NON-PATENT DOCU	IMENTS Victor Edition or Volume, Pertinent Pa	ages)

Include as applicable: Author, Title Date, Following Adjei et al. Docetaxel and Irinotecan, Alone and in combination, in the treatment of non-small cell lung cancer. Seminars in Oncology, 1999 Vol. 26:32-40. V. Foran et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed lymphoplasmacytoid Mantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553. W. Murren et al. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel patients with advance cancer. Caner Chemotherapy Pharmacology, 2000 Vol. 46:43-50.			Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
Foran et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed lymphoplasmacytoid Wantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553. Mantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553.	\perp	_	Along and in combination, in the treatment of non-small cell lung cancer. Germinal and
Foran et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed lymphoplasmacytoid Wantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553. Mantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553.	1		Adjei et al. Docetaxel and Irinotecan, Alone and in Johnson
Foran et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed lymphopal V. Foran et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed lymphopal V. Mantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553. Mantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553.	1	0 1	Oncology, 1999 Vol. 26:32-40.
Mantle-cell lymphoria. Souther the study of irinotecan in combination with paclitaxel patients with advance	1	1	Phosphate for Patients with Newly Diagnosed lymphop
Mantie-cell lymphoria. Souther of Mantie-cell lymphoria. Souther of the Mantie-cell lymphoria. Souther of the Mantie-cell lymphoria.	1	1	Foran et al. Multicenter Phase II Study of Fludal ability 1999 Vol. 17:546-553.
a sackingtic study of irinotecan in combination with pacificacity pacification	١	٧.	Mantle-cell lymphoma. Journal of Cliffical Oriology
W Murren et al. Dose escalation and pharmacokinetic study of the study	1		a cacking tic study of irinotecan in combination with pacitical particular pacitics.
cancer. Caner Chemotherapy Pharmacology, 2000 vol. 1	1		Murren et al. Dose escalation and pharmacokinetic Vol. 46:43-50.
	١	W :	cancer. Caner Chemotherapy Pharmacology, 2000 Volume
		X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.